Liquid Biopsy Markets: Global Analysis and Opportunity Evaluation

Current and 3-year CTC activity disclosures provided by 482 scientists and clinicians Growth in CTC tests and estimated growth over the next 3 years (±% change) End-users' estimates of the costs per patient, for CTC tests CTC detection/enrichment platforms used currently and in 3 years (±% change) Company CTC platforms used currently and over the next 3 years (±% change) CTC parameters or measurements now and in 3 years (±% change) Non-Molecular techniques used with CTCs, currently and in 3 years (±% change) Molecular techniques used with CTCs, now and in 3 years (±% change) Suppliers of molecular techniques currently and anticipated in 3 years (±% change) Markers used to enrich or characterise CTCs now and in 3 years (±% change) CTC subpopulation studies currently and anticipated in 3 years (±% change) Molecular forms studied currently and anticipated in 3 years (±% change) Molecular biomarkers studied currently and anticipated in 3 years (±% change) Sample types studied currently for the purpose of CTC studies End-users' disclosures on the clinical utilities of CTCs in diagnostics Cancer types studied relating to the study of CTCs Purpose of studies relating to CTCs Limitations of current studies of CTCs Fields or sectors Global regions, countries and organisation types The study or investigation of CTCs in drug R&D The study or investigation of CTC in drug R&D by R&D development phase The use of CTCs as companion diagnostics now and in 3 years (±% change)